In the Margins

Sequoia Fund manager details Valeant experience

March 1, 2016

By Barron's

In its annual report, Sequoia Fund manager Ruane, Cuniff & Goldfarb has vented about Valeant Pharmaceuticals' recent stock plunge, though it offers an optimistic outlook for the stock. The letter outlines how much Valeant’s relationship with affiliated pharmacy Philidor wreaked havoc for the fund company. Read the original story from Barron's.

 

 

Most Read

Top of the Agenda - Regulatory
2010-2020: A decade of regulatory developments

There certainly has been considerable change over the past 10+ years in the investment company industry and its regulation. From 2010 to 2020, the net assets ...